Material Agreement, Financial Obligation (Form 8-K)

The information set forth below in Item 2.03 is incorporated by reference into this Item 1.01.

On September 22, 2026, Tenet Healthcare Corporation (the "Company") issued $2,000,000,000 in aggregate principal amount of 6.250% senior notes due 2034 (the "Notes"). The Notes were issued pursuant to an indenture, dated as of November 6, 2001 (the "Base Indenture"), between the Company and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York as trustee (in such capacity, the "Trustee"), as supplemented by the forty-third supplemental indenture, dated as of September 22, 2026, between the Company and the Trustee (the "Forty-Third Supplemental Indenture" and, the Base Indenture, as supplemented by the Forty-Third Supplemental Indenture, the "Indenture").

The Company intends to use the net proceeds from the sale of the Notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion outstanding of its 5.125% senior secured first lien notes due November 2027 (the "2027 Notes") and the partial redemption of $0.5 billion outstanding of its 6.125% senior notes due October 2028 (the "2028 Notes").

The Indenture contains covenants that, among other things, restrict the Company's ability and the ability of its subsidiaries to: incur liens; enter into sale and lease-back transactions; or consolidate, merge or sell all or substantially all of their assets, other than in certain transactions between one or more of the Company's wholly owned subsidiaries and the Company. These restrictions, however, are subject to a number of important exceptions and qualifications. In particular, there are no restrictions on the Company's ability or the ability of its subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities).

The Indenture also provides that the Notes may become subject to redemption under certain circumstances, including a change of control (as defined in the Indenture) of the Company. Prior to September 15, 2029, the Company may, at its option, redeem the Notes in whole or in part, at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus the make-whole premium set forth in the Indenture, together with accrued and unpaid interest. On and after September 15, 2029, the Company may, at its option, redeem the Notes in whole or in part, at certain redemption prices (expressed as percentages of the principal amount thereof) set forth in the Indenture, together with accrued and unpaid interest.

The foregoing is a summary and is qualified by reference to the Base Indenture and the Forty-Third Supplemental Indenture, which are filed herewith as Exhibits 4.1 and 4.2, respectively, and are incorporated herein by reference.